择期分支腔内修复术后抗血栓治疗与桥接支架通畅性的多中心国际队列研究
该国际多中心回顾性分析纳入4个欧洲三级血管中心2014年1月至2022年12月间120例择期分支腔内主动脉修复术患者,评估术后抗血栓治疗对桥接支架闭塞率的影响。中位随访21个月,桥接支架闭塞率为5.8%,肾动脉桥接支架闭塞风险显著高于内脏动脉(p=0.013),多变量Cox模型显示不同抗血栓策略间无显著差异。
要点
- 择期分支腔内主动脉修复术后桥接支架闭塞率为5.8%,肾动脉分支闭塞率高于内脏分支。
- 多变量Cox分析显示所用抗血栓策略间桥接支架闭塞无显著差异。
- 因桥接支架闭塞例数少,该研究既不能支持也不能否定PRINCE2SS推荐。
核心结论
- 桥接支架闭塞率总体较低,肾动脉桥接支架闭塞率显著高于内脏动脉桥接支架。
- 无任何抗血栓治疗与桥接支架闭塞显著相关,也未发现其他抗血栓治疗优效的证据。
- 由于桥接支架闭塞例数少,该研究既不能支持也不能否定PRINCE2SS推荐,需更大队列进一步研究以确定复杂腔内主动脉修复术后最佳抗血栓治疗方案。
研究设计与样本
- 国际多中心回顾性分析,纳入4个欧洲三级血管中心2014年1月至2022年12月间接受择期分支腔内主动脉修复术的患者。
- 纳入使用现成或定制分支支架移植物治疗肾旁主动脉瘤、既往EVAR后Ia型内漏及胸腹主动脉瘤的患者中所有以桥接支架处理的肾内脏靶血管。
- 共纳入120例患者(90例男性),中位年龄72岁(IQR=67-77),使用289个外分支和127个内分支处理416条靶血管。
- 中位随访21个月(IQR=9-48),随访指数为1.0,随访信息截至2022年12月31日。
主要发现
- 随访期间发现24例(5.8%)原发性桥接支架闭塞,其中左肾动脉10例、右肾动脉7例、肠系膜上动脉3例、腹腔干4例。
- 肾动脉桥接支架闭塞风险显著高于内脏桥接支架(p=0.013)。
- 肾分支1年闭塞率为7.8%、5年为10.6%,内脏分支1年闭塞率为1.5%、5年为3.7%。
- 多变量Cox比例风险模型显示所用抗血栓策略间桥接支架闭塞无显著差异。
局限性
- 由于桥接支架闭塞例数少,该研究既不能支持也不能否定PRINCE2SS推荐。
- 需更大队列的进一步研究以确定复杂腔内主动脉修复术后最佳抗血栓治疗方案的明确指南。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The risk of bridging stent occlusion after branched endovascular aortic repair (BEVAR) remains an issue. Currently, there is no clear recommendation on what kind of antithrombotic therapy should be installed after BEVAR. The aim of the study was to estimate the impact of postoperative antithrombotic therapy on bridging stent occlusion rate after elective BEVAR. An international multicenter retrospective analysis was performed in 4 European tertiary vascular units. All reno-visceral target vessels treated with bridging stents of patients undergoing elective BEVAR with the use of off-the-shelf or custom-made branched stent-grafts for pararenal aortic aneurysms (PAAs), type Ia endoleaks after previous EVAR, and thoracoabdominal aortic aneurysms (TAAA) between January 2014 and December 2022 were included. Primary outcome was freedom from bridging stent occlusion and its correlation with postoperative antithrombotic therapy. Secondary outcomes were overall survival and identifying target vessel and bridging stent characteristics, which may have a higher risk for bridging stent occlusion according to the PRINCE2SS recommendation. Follow-up information was obtained for all patients per 31st of December 2022. In total, 120 patients (90 male) with a median age of 72 (interquartile range [IQR]=67-77) years were included. Two hundred eighty-nine external and 127 internal branches were used for 416 target vessels. The median follow-up was 21 months (IQR=9-48) with a follow-up index of 1.0. During follow-up, 24 (5.8%) primary bridging stent occlusions (left renal artery [LRA]=10, right renal artery [RRA]=7, superior mesenteric artery [SMA]=3, truncus coeliacus [TC]=4) were found. The risk of renal bridging stent occlusion is significantly higher compared with visceral bridging stent, p=0.013. The occlusion rate was 7.8% for renal branches and 1.5% for visceral branches at 1 year and 10.6% and 3.7% at 5 years, respectively. The multivariable Cox proportional hazard model on bridging stent occlusion showed that there was no significant difference between the used antithrombotic strategies. No antithrombotic therapy was significantly associated with bridging stent occlusion, whereas no evidence for superiority of any other antithrombotic therapy was found. Overall, the bridging stents' occlusion rate was low. We found a significantly higher occlusion rate in renal arteries compared with the visceral ones.Clinical ImpactBased on our study, no antithrombotic therapy is significantly associated with bridging stent occlusion, and no evidence of the superiority of other antithrombotic therapy exists. Nevertehless, due to the low number of bridging stent occlusions, this study can neither support nor reject the PRINCE2SS recommendations. Further studies with larger cohorts are needed to determine clear guideliness of the best antithrombotic treatment regimen after complex enfovascular aortic repair.
引用
- Dabravolskaite V, Meuli L, Yazar O, et al. Antithrombotic Therapy and Freedom From Bridging Stent Occlusion After Elective Branched Endovascular Repair: A Multicenter International Cohort Study. J Endovasc Ther. 2024. PMID: 38798060. doi:10.1177/15266028241253133
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。